Thrombogenic Side-Effects of Recombinant Factor Viia After Use in Coronary Artery Bypass Surgery (Case Report)
Anaesthesia and Intensive Care 2006, Oct, 34, 5
-
- $5.99
-
- $5.99
Publisher Description
SUMMARY Recombinant activated factor VII (rFVIIa) has been used 'off licence' to successfully treat bleeding and reduce transfusion requirements in complex cardiac surgery. However, concerns over thrombogenic side-effects have limited but not excluded its use in patients undergoing coronary artery bypass surgery (CABG).
More Books by Anaesthesia and Intensive Care
Anaesthetic Implications of Vascular Type Ehlers-Danlos Syndrome.
2006
Monitoring of Extubated Patients: Are Routine Arterial Blood Gas Measurements Useful and How Long should Patients be Monitored in the Intensive Care Unit?(Report)
2010
Preventing Pain on Injection of Propofol: A Comparison Between Peripheral Ketamine Pre-Treatment and Ketamine Added to Propofol (Report)
2009
Scout's Motto (Report)
2009
Vocal Cords-Carina Distance in Anaesthetised Caucasian Adults and Its Clinical Implications for Tracheal Intubation (Report)
2010
A Randomised, Single-Blind, Controlled Trial of Silicone Disposable Laryngeal Masks During Anaesthesia in Spontaneously Breathing Adult Patients (Report)
2009